FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Keytruda Gets FDA Nod for Kidney Cancer

April 30, 2019
A A

The FDA approved Merck’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) for treatment of patients with advanced renal cell carcinoma.

The expanded approval comes after Merck reported data from a Phase III trial, which found that Keytruda cut the risk of patient death nearly in half.

Keytruda is already a blockbuster for Merck as a lung cancer drug, with $2 billion in sales in the fourth quarter of 2018 alone.

Advanced renal cell carcinoma is the most common form of kidney cancer.

View today's stories